Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel and apatinib in advanced triple-negative breast cancer
CTR20200606Phase 3Terminated
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Apr 2020; status: terminated.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20200606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200606.